Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 18Unknown 10Terminated 10Recruiting 7Active not recruiting 6Not yet recruiting 3Withdrawn 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

Cisplatin 22Carboplatin 15Radiotherapy 13Paclitaxel 11Gemcitabine 10Rituximab 9Fluorouracil 9Drug Therapy 6Dexamethasone 5Cyclophosphamide 5Capecitabine 5Bevacizumab 5Vinorelbine 4Pemetrexed 4Nivolumab 4Methotrexate 4Etoposide 4Docetaxel 4Bendamustine Hydrochloride 4spartalizumab 3pertuzumab 3pembrolizumab 3fludarabine 3Vincristine 3Trastuzumab 3Surgical Procedures, Operative 3Standard of Care 3Prednisone 3Oxaliplatin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × Mitomycin × Clear all
NCT04006691 2020-05-07

Retreatment

UroGen Pharma Ltd.

Phase 3 Withdrawn
Genitourinary

Carcinoma, Carcinoma, Transitional Cell

NCT01327521 2012-06-11

Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma

Stanford University

Phase 3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡